{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:54:52Z","timestamp":1781499292176,"version":"3.54.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term prospective real-world data on anti\u2013IL-5 and anti\u2013IL-5 receptor biologics in eosinophilic granulomatosis with polyangiitis (EGPA) are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this 24-month prospective single-center observational study, 66 adults with EGPA received benralizumab 30 mg (every 4 weeks for the first three doses, then every 8 weeks), mepolizumab 300 mg every 4 weeks or mepolizumab 100 mg every 4 weeks. Remission was defined as BVASv3\u00a0=\u00a00 with prednisone \u22645 mg\/day. Glucocorticoid (GC)-free status was defined as no oral GCs. The primary analysis was conducted in patients starting biologics as first-line. To address confounding by indication, we performed multivariable logistic regression and multinomial propensity score inverse probability weighting (IPTW). Analyses were repeated in an all-lines dataset (81 treatment lines) using generalized estimating equations (GEE) clustered by patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinical outcomes improved over the 24-month follow-up across all regimens. By 24 months, remission was 73.7% (14\/19) with benralizumab, 81.0% (17\/21) with mepolizumab 300 mg, and 50.0% (6\/12) with mepolizumab 100 mg, without statistically significant differences between regimens. GC-free status increased over time, reaching 63.2% (12\/19) with benralizumab, 85.7% (18\/21) with mepolizumab 300 mg, and 58.3% (7\/12) with mepolizumab 100 mg at 24 months, with no significant between-group differences. Adjusted and propensity-based sensitivity analyses yielded consistent conclusions. Eosinophils decreased markedly, with near-complete suppression with benralizumab. Pulmonary function indices showed improvement during follow-up, with the clearest within-group improvement observed in the benralizumab group. Treatment persistence at 24 months varied across regimens, although no statistically significant difference was observed (log-rank p=0.222). Discontinuations were mainly driven by inadequate control of ENT or respiratory manifestations. In all-lines GEE analyses, regimen effects on remission and GC-free status were broadly consistent with the primary analysis. Adverse events were uncommon and no serious events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anti\u2013IL-5\/IL-5R biologics were effective and well tolerated over 24 months in EGPA, with substantial GC sparing effect. The observational design and potential confounding by indication limit comparative effectiveness inference. These findings support individualized biologic selection in EGPA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1844354","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:26:40Z","timestamp":1781497600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Marta","family":"Codirenzi","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Davanzo","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Iorio","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Fiorin","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Guarnieri","sequence":"additional","affiliation":[{"name":"Respiratory Pathophysiology Division, Department of Cardio-Thoracic-Vascular Sciences, University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Chieco Bianchi","sequence":"additional","affiliation":[{"name":"Respiratory Pathophysiology Division, Department of Cardio-Thoracic-Vascular Sciences, University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Achille","sequence":"additional","affiliation":[{"name":"Respiratory Pathophysiology Division, Department of Cardio-Thoracic-Vascular Sciences, University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Marchi","sequence":"additional","affiliation":[{"name":"Respiratory Unit, Cittadella Hospital, ULSS6 Euganea","place":["Cittadella, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vianello","sequence":"additional","affiliation":[{"name":"Respiratory Pathophysiology Division, Department of Cardio-Thoracic-Vascular Sciences, University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Padoan","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine (DIMED), University of Padua","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in health and disease: A state-of-the-art review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: A European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol Hoboken Nj"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.025","article-title":"Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase","volume":"9","author":"Caminati","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: Data from a European collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2581812","article-title":"Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience","volume":"57","author":"Davanzo","year":"2025","journal-title":"Ann Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00243-6","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study","volume":"5","author":"Bettiol","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103503","article-title":"Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis","volume":"23","author":"Davanzo","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B17","unstructured":"Serious adverse reaction"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202106-653OC","article-title":"Novel methods of measuring adherence patterns reveal adherence phenotypes with distinct asthma outcomes","volume":"19","author":"Huvanandana","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.12.983","article-title":"Asthma outcomes: exacerbations","volume":"129","author":"Fuhlbrigge","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.01.006","article-title":"Long-term effectiveness of benralizumab in eosinophilic granulomatosis with polyangiitis","volume":"12","author":"Nanzer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103398","article-title":"Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study","volume":"153","author":"Mattioli","year":"2025","journal-title":"J Autoimmun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1204444","article-title":"Effectiveness and safety of anti-IL-5\/R\u03b1 biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study","volume":"14","author":"Nolasco","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-00507-0","article-title":"Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts","volume":"17","author":"Ghassemian","year":"2021","journal-title":"Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S461800","article-title":"Benralizumab reduces respiratory exacerbations and oral glucocorticosteroid dose in patients with severe asthma and eosinophilic granulomatosis with polyangiitis","volume":"17","author":"M\u00fcmmler","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224624","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis","volume":"82","author":"Cottu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2022.14.5.465","article-title":"Interpretation of clinical efficacy of biologics in chronic rhinosinusitis with nasal polyps via understanding the local and systemic pathomechanisms","volume":"14","author":"Yang","year":"2022","journal-title":"Allergy Asthma Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae554","article-title":"Dupilumab for refractory chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis","volume":"64","author":"Padoan","year":"2025","journal-title":"Rheumatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1844354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:26:48Z","timestamp":1781497608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1844354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1844354"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1844354","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"1844354"}}